Protagonist Therapeutics, Inc. (PTGX) Earnings Call Transcripts
Protagonist Therapeutics, Inc.'s Latest Earnings Call - June 10, 2026
Protagonist Therapeutics reported its earnings for Q2 2026, highlighting significant developments that could impact its stock. The company is now a commercial entity with its drug cotide, partnered with J&J, and anticipates the approval of rusfertide in Q3 2026. CEO Dinesh Patel emphasized the potential approval as a key milestone, with Phase III data described as 'outstanding.' The company did not provide specific revenue or earnings figures but indicated a strong financial position, suggesting no need for equity raises and potential share buybacks contingent on rusfertide's approval. Management maintained its guidance, focusing on the approval of rusfertide and the expansion of its R&D pipeline.
Reported metrics
| Metric | Value |
|---|---|
| Rusfertide Peak Sales | $1 billion to $2 billion (inline) |
| Cotide Prescribers | 4,500+ (positive) |
| Cotide Peak Sales | $10 billion to $15 billion (positive) |
| Royalty Rate for Rusfertide | 14% to 29% (positive) |
Guidance from management
Management maintained guidance, focusing on rusfertide's approval in Q3 2026. No changes to revenue or earnings guidance were provided.
What management said
Yes. So -- we are waiting for the approval of rusfertide because that will really cement our revenue projections. That's the key gating factor right now. And we are not fond of onetime share buybacks. If we do it, we'll do it the right way, have a steady share buyback program.
Right, right. So in the next readout of the PSA, the psoriatic arthritis -- so that disease is becoming more of an IL-17 disease. I think you look at what's going on because they're able to address the joint as well as the skin.
What analysts pressed on
Analysts expressed concerns about the competitive landscape for the IL-17 and obesity programs, questioning the differentiation and commercial strategy. There were also questions about the potential impact of rusfertide's pricing and market adoption.
Main topics on the call
- Rusfertide Approval — Protagonist anticipates rusfertide's approval in Q3 2026, with a PDUFA date in August. The Phase III data has been described as 'outstanding,' and approval would make Protagonist a biotech with two approved drugs this ye...
- Cotide Commercialization — Cotide, partnered with J&J, is experiencing a strong launch with over 4,500 prescribers since its approval. J&J projects peak sales between $10 billion and $15 billion, with potential market share gains from injectables.
- Financial Position — Protagonist claims to have ample cash due to royalty and milestone arrangements with J&J and Takeda, negating the need for equity raises. Management hinted at potential share buybacks post-rusfertide approval.
- R&D Pipeline Expansion — The company is focusing on expanding its R&D pipeline, emphasizing validated biology targets and a higher probability of success. The IL-17 program is highlighted as a significant opportunity.
Read the full Protagonist Therapeutics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 31 calls on record spanning March 10, 2020 to September 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 31 Protagonist Therapeutics, Inc. earnings call transcripts on record, spanning March 10, 2020 to September 9, 2026. Based on this history, Protagonist Therapeutics, Inc. reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PTGX
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 31
- First call
- March 10, 2020
- Most recent
- September 9, 2026
- Reporting cadence
- quarterly